Positive clinical trial results are a strong indicator of potential future success for biotech companies, both in terms of regulatory approval and market acceptance. For Calliditas, these results could lead to increased investor confidence, potentially driving up the stock price in the short term. The data's consistency and the study's significance in addressing IgAN (a chronic kidney disease) underscore the potential market impact and the importance of these findings for investors.